%0 Journal Article
%A Baertsch, Marc-Andrea
%A Schlenzka, Jana
%A Lisenko, Katharina
%A Krzykalla, Julia
%A Becker, Natalia
%A Weisel, Katja
%A Noppeney, Richard
%A Martin, Hans
%A Lindemann, Hans W
%A Haenel, Mathias
%A Nogai, Axel
%A Scheid, Christof
%A Salwender, Hans
%A Fenk, Roland
%A Graeven, Ullrich
%A Reimer, Peter
%A Schmidt-Hieber, Martin
%A Goerner, Martin
%A Schmidt-Wolf, Ingo G H
%A Klein, Stefan
%A Ho, Anthony D
%A Goldschmidt, Hartmut
%A Wuchter, Patrick
%T Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.
%J European journal of haematology
%V 99
%N 1
%@ 0902-4441
%C Oxford
%I Wiley-Blackwell
%M DKFZ-2017-01329
%P 42 - 50
%D 2017
%X Analysis of the efficiency and toxicity of cyclophosphamide-based stem cell mobilization in patients with relapsed multiple myeloma (RMM).Peripheral blood stem cells (PBSCs) were mobilized with high dose cyclophosphamide (2 g/m(2) daily on days 1 and 2) and G-CSF plus pre-emptive/rescue plerixafor in RMM patients (first to third relapse) treated within the ReLApsE trial of the German-Speaking Myeloma Multicenter Group (GMMG).Mobilization was initiated with high-dose cyclophosphamide (HD-CY) and G-CSF in 30 patients. Fifteen patients received additional pre-emptive/rescue administration of plerixafor. Stem cell collection was successful (≥2×10(6) CD34+ cells per kg bw) in 77
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:28370401
%R 10.1111/ejh.12888
%U https://inrepo02.dkfz.de/record/124452